Literature DB >> 8629585

Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris.

R W Hautvast1, P K Blanksma, M J DeJongste, J Pruim, E E van der Wall, W Vaalburg, K I Lie.   

Abstract

Spinal cord stimulation in angina pectoris increases exercise capacity and reduces both anginal attacks and ischemic electrocardiographic signs. This suggests an anti-ischemic action, perhaps through changes in myocardial blood flow. In 9 patients, regional myocardial blood flow was studied with positron emission tomography before and after 6 weeks of spinal cord stimulation, both at rest and during a dipyridamole stress test. Frequency of anginal attacks and consumption of short-acting nitrates were assessed by patient diaries. Exercise duration and time to angina were measured with treadmill exercise tests. After 6 weeks of stimulation, both frequency of daily anginal attacks and nitrogen consumption decreased (3.7 +/- 1.7 vs 1.4 +/- 1.0 [p <0.01] and 2.8 +/- 2.2 vs 1.1 +/- 1.2 tablets [p = 0.01], respectively); exercise duration and time to angina increased (358 +/- 165 vs 493 +/- 225 seconds [p <0.01] and 215 +/- 115 vs 349 +/- 213 seconds [p = 0.02], respectively); and ST-segment depression during dipyridamole stress testing was reduced (0.17 [0 to 0.5] mV vs 0.09 [0 to 0.2] mV, p = 0.04) (all data mean +/- SD). Total resting blood flow remained unchanged (115 +/- 29 vs 127 +/- 31 ml/min/100 g, p = 0.31), but flow reserve decreased (146 +/- 43% vs 122 +/- 39%, p = 0.04). The coefficient of variation of flow, representing flow heterogeneity, decreased after treatment, both at rest (20.1 +/- 3.8% vs 17.4 +/- 2.6%, p = 0.04) and after dipyridamole stress (26.2 +/- 4.4% vs 22.9 +/- 5.5%, p = 0.02). Thus, spinal cord stimulation is clinically effective due to homogenization of myocardial blood flow. Since flow reserve decreases despite clinical improvement, the dipyridamole effect may be blunted by spinal cord stimulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8629585     DOI: 10.1016/s0002-9149(97)89338-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  26 in total

Review 1.  Neurostimulation treatment for angina pectoris.

Authors:  S Murray; P D Collins; M A James
Journal:  Heart       Date:  2000-02       Impact factor: 5.994

Review 2.  Spinal cord stimulation: an update.

Authors:  Steven Falowski; Amanda Celii; Ashwini Sharan
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

Review 3.  Recent advances: control of chronic pain.

Authors:  T J Nurmikko; T P Nash; J R Wiles
Journal:  BMJ       Date:  1998-11-21

4.  Long-term outcome of spinal cord electrical stimulation in patients with refractory chest pain.

Authors:  J P Bagger; B S Jensen; G Johannsen
Journal:  Clin Cardiol       Date:  1998-04       Impact factor: 2.882

5.  Advances in spinal cord stimulation.

Authors:  J P Prager
Journal:  West J Med       Date:  1997-03

Review 6.  An overview of treatment approaches for chronic pain management.

Authors:  Nicholas Hylands-White; Rui V Duarte; Jon H Raphael
Journal:  Rheumatol Int       Date:  2016-04-23       Impact factor: 2.631

Review 7.  Application of animal and human PET in cardiac research.

Authors:  Quan Wang; Zhi-Gang He; Shun-Yuan Li; Mao-Hui Feng; Hong-Bing Xiang
Journal:  Am J Cardiovasc Dis       Date:  2018-06-15

Review 8.  Supraspinal Mechanisms of Spinal Cord Stimulation for Modulation of Pain: Five Decades of Research and Prospects for the Future.

Authors:  Eellan Sivanesan; Dermot P Maher; Srinivasa N Raja; Bengt Linderoth; Yun Guan
Journal:  Anesthesiology       Date:  2019-04       Impact factor: 7.892

Review 9.  Management of Refractory Angina Pectoris.

Authors:  Kevin Cheng; Paul Sainsbury; Michael Fisher; Ranil de Silva
Journal:  Eur Cardiol       Date:  2016-12

Review 10.  Treatment of refractory angina in patients not suitable for revascularization.

Authors:  Timothy D Henry; Daniel Satran; E Marc Jolicoeur
Journal:  Nat Rev Cardiol       Date:  2013-12-24       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.